Literature DB >> 26907959

Increased regulatory T cells in acute lymphoblastic leukaemia patients.

Siti-Zuleha Idris1, Norfarazieda Hassan1, Le-Jie Lee1, Sabariah Md Noor1, Raudhawati Osman2, Marsitah Abdul-Jalil1, Abdul-Jalil Nordin1, Maha Abdullah1.   

Abstract

INTRODUCTION: Regulation in adaptive immune response balances a fine line that prevents instigation of self-damage or fall into unresponsiveness permitting abnormal cell growth. Mechanisms that keep this balance in check include regulatory T cells (Tregs). Tregs consist of a small but heterogeneous population, which may be identified by the phenotype, CD3+CD4+CD25+CD127-. The role of Tregs in pathogenesis of cancers is thus far supported by evidence of increased Tregs in various cancers and may contribute to poorer prognosis. Tregs may also be important in acute leukaemias.
OBJECTIVE: A review of the literature on Tregs in acute leukaemias was conducted and Tregs were determined in B-cell acute lymphoblastic leukaemias (ALLs).
RESULTS: Studies on Tregs in B-cell ALL are few and controversial. We observed a significantly increased percentage of Tregs (mean±SD, 9.72 ± 3.79% vs. 7.05 ± 1.74%; P = 0.047) in the bone marrow/peripheral blood of ALL (n = 17) compared to peripheral blood of normal controls (n = 35). A positive trend between Tregs and age (R = 0.474, P = 0.055, n = 17) implicates this factor of poor prognosis in B-cell ALL. DISCUSSION: Tregs in cancer are particularly significant in immunotherapy. The manipulation of the immune system to treat cancer has for a long time ignored regulatory mechanisms inducible or in place. In lymphoma studies, tumour-specific mechanisms that are unlike conventional methods in the induction of Tregs have been hypothesized. In addition, tumour-infiltrating Tregs may present different profiles from peripheral blood pictures. Tregs will continue to be dissected to reveal its mysteries and their impact on clinical significance.

Entities:  

Keywords:  Age; B-cell acute lymphoblastic leukaemia; Regulatory T cells

Mesh:

Year:  2016        PMID: 26907959     DOI: 10.1080/10245332.2015.1101965

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  7 in total

1.  Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.

Authors:  Chunlei Ge; Ruilei Li; Haifeng Song; Tao Geng; Jinyan Yang; Qinghua Tan; Linfeng Song; Ying Wang; Yuanbo Xue; Zhen Li; Suwei Dong; Zhiwei Zhang; Na Zhang; Jiyin Guo; Lin Hua; Siyi Chen; Xin Song
Journal:  BMC Cancer       Date:  2017-12-21       Impact factor: 4.430

Review 2.  Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.

Authors:  Jochen Greiner; Marlies Götz; Donald Bunjes; Susanne Hofmann; Verena Wais
Journal:  J Clin Med       Date:  2019-12-23       Impact factor: 4.241

3.  Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia.

Authors:  Yuling Wan; Congxiao Zhang; Yingxi Xu; Min Wang; Qing Rao; Haiyan Xing; Zheng Tian; Kejing Tang; Yingchang Mi; Ying Wang; Jianxiang Wang
Journal:  BMC Cancer       Date:  2020-05-26       Impact factor: 4.430

4.  Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.

Authors:  Furun An; Huiping Wang; Zhenyun Liu; Fan Wu; Jiakui Zhang; Qianshan Tao; Yingwei Li; Yuanyuan Shen; Yanjie Ruan; Qing Zhang; Ying Pan; Weiwei Zhu; Hui Qin; Yansheng Wang; Yongling Fu; Zhenqing Feng; Zhimin Zhai
Journal:  Nat Commun       Date:  2020-11-23       Impact factor: 14.919

Review 5.  Toward Therapeutic Targeting of Bone Marrow Leukemic Niche Protective Signals in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Marjorie C Delahaye; Kaoutar-Insaf Salem; Jeoffrey Pelletier; Michel Aurrand-Lions; Stéphane J C Mancini
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

Review 6.  Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia.

Authors:  Silvia Jiménez-Morales; Ivan Sammir Aranda-Uribe; Carlos Jhovani Pérez-Amado; Julian Ramírez-Bello; Alfredo Hidalgo-Miranda
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

7.  HSH2D contributes to methotrexate resistance in human T‑cell acute lymphoblastic leukaemia.

Authors:  Jing Wang; Yiying Xiong
Journal:  Oncol Rep       Date:  2020-09-17       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.